Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine (Q34182017)

31 July 2017

title

Treatment of postinfectious irritable bowel syndrome and noninfective irritable bowel syndrome with mesalazine (English)

1 reference

31 July 2017

main subject

irritable bowel syndrome

1 reference

Mauro Bafutto

1

1 reference

31 July 2017

José Roberto de Almeida

2

1 reference

31 July 2017

Nayle Vilela Leite

3

1 reference

31 July 2017

Enio Chaves Oliveira

4

1 reference

31 July 2017

Salustiano Gabriel-Neto

5

1 reference

31 July 2017

Joffre Rezende-Filho

6

1 reference

31 July 2017

publication date

1 January 2011

1 reference

Arquivos de Gastroenterologia

31 July 2017

published in

1 reference

31 July 2017

volume

48

1 reference

31 July 2017

issue

1

1 reference

31 July 2017

page(s)

36-40

1 reference

Mechanisms underlying the maintenance of muscle hypercontractility in a model of postinfective gut dysfunction

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

New pathophysiological mechanisms in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

The role of psychological and biological factors in postinfective gut dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Inhibition of nuclear factor kappa B and induction of apoptosis in T-lymphocytes by sulfasalazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Prognosis in post-infective irritable bowel syndrome: a six year follow up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Post-infectious irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Role of infection in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1590%2FS0004-28032011000100008

10.1590/S0004-28032011000100008

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference